In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 176 to 200 of 437

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Hearing aids for adults with hearing loss	Health technology evaluation	27 January 2027
Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)	NICE guideline	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]	Technology appraisal guidance	TBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance	TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death	Interventional procedures guidance	19 November 2026
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]	Technology appraisal guidance	TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	12 June 2026
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	21 May 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin efsitora alfa for treating type 2 diabetes ID6499	Technology appraisal guidance	22 October 2026
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]	Technology appraisal guidance	26 August 2026
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]	Technology appraisal guidance	TBC

Results per page

10
25
50
All